Introduction
In sub-Saharan Africa, a substantial geographic overlap between areas with high sexually transmitted infection (STI) and HIV prevalence has been recognized since early in the HIV epidemic. Recognition of this geographic overlap led to the hypothesis that STIs could influence HIV transmission [1, 2] . However, treatment of STIs has failed to reduce HIV incidence in the majority of clinical trials [3] , raising questions about whether STI treatment for HIV control is a feasible prevention tool [4] . In an effort to understand the inconsistency between findings from observational studies and clinical trials, several hypotheses have been advanced [5] [6] [7] [8] . The most widely accepted hypothesis suggests that the contribution of STIs to new HIV infections may change over time as an HIV epidemic matures [6] . In an early epidemic, the proportion of new HIV infections attributable to treatable STIs is much higher than at later stages [9, 10] . As the epidemic matures, there is a shift towards a greater proportion of HIV transmission attributable to chronic STIs such as herpes simplex virus type 2 (HSV-2) [11] . One modelling study has demonstrated that time since introduction of HIV in a community influences the contribution of STIs to HIV acquisition and an increase in the importance of HSV-2 as the HIV epidemic matures. In contrast, a meta-analysis assessing trends in HIV risk concluded that risk factors for HIV have remained relatively unchanged as the epidemic has matured [12] .
To address the question of how the role of STIs in HIV acquisition has changed over time in a high-risk population, we sought to determine how the relative contribution of different STIs to HIV acquisition has changed over the past two decades. Our goals were to estimate the PAR% of various genital tract conditions to HIV acquisition in a cohort of HIV-seronegative high-risk women in Mombasa, Kenya. We then tested the hypothesis that the PAR% of different STIs would change significantly over the 20 years of observation.
Materials and methods
We conducted longitudinal follow-up of women participating in the Mombasa Cohort, an open cohort study of high-risk Kenyan women, between February 1993 and December 2012. The eligibility criteria were age 18-50 years, residing in the Mombasa area, selfidentifying as exchanging sex for cash or in-kind payment and able to provide informed consent. This study was approved by the ethics boards of Kenyatta National Hospital, the University of Washington and the Fred Hutchinson Cancer Research Center. All participants provided informed consent for participation.
Clinic procedures
At enrolment, a study nurse conducted a standardized interview detailing demographic data, medical, gynaecological and sexual history. A study physician performed a physical examination including a pelvic speculum examination with collection of swabs of cervical and vaginal secretions for STI testing. Blood was collected for HIV and HSV-2 testing. Women were asked to return for their results a week later. Following enrolment, women were scheduled for monthly follow-up visits, updated risk factor data were collected and repeat testing for STIs and HIV were performed. Participants received free outpatient medical services including treatment of STIs according to WHO [13] and Kenyan national guidelines. Syndromic management was offered during examination visits if indicated. At the results visit 1 week later, additional treatment was provided if indicated by the laboratory test results. [14] . Normal saline wet mounts were examined microscopically at 40X power for the presence of motile trichomonads, clue cells and yeast. Culture for Neisseria gonorrhoeae was performed on modified Thayer-Martin media. Cervical Gram's-stained slides were examined microscopically for the number of polymorphonuclear granulocytes, with a count of at least 30 being considered as cervicitis. Starting in August 2006, endocervical samples were tested for N. gonorrhoeae and Chlamydia trachomatis by transcription mediated amplification using the Gen-Probe APTIMA GC/CT Detection System (Hologic/Gen-Probe, San Diego, California, USA). Because the Chlamydia data do not span the entire period of cohort participation, they were not used for this study. Serological testing for HSV-2 was performed using a type-specific HSV-2 gG based ELISA (HerpeSelect 2; Focus Diagnostics, Cypress, California, USA). An index value of greater than or equal to 2.1 [the ratio of the optical density (OD) of the sample to the OD of the standard calibrator] was considered positive [15] . Syphilis testing was performed every 3 months using rapid plasma reagin (RPR). Further testing using Treponema pallidum hemagglutination (TPHA) was conducted for RPR-positive samples. When present, ulcers were cultured for Hemophilus ducreyi. As syphilis and H. ducreyi data were not collected monthly, these data were not included in the analyses.
Laboratory procedures

Data analyses
This study was conducted between February 1993 and December 2012. This 20-year period was grouped into four time periods of five years each: 1993-1997, 1998-2002, 2003-2007, 2008-2012 . Only women who were HIV seronegative at enrolment were included. The primary exposures were vulvovaginal candidiasis, bacterial vaginosis (Nugent score 7-10) [14] . Intermediate vaginal microbiota (Nugent score 4-6), Trichomonas vaginalis, N. gonorrhoeae, nonspecific cervicitis, prevalent HSV-2, incident HSV-2, genital ulcer disease (GUD) and genital warts. The outcome was time to HIV acquisition. We determined the incidence rates of each genital tract condition overall and for each time period, allowing repeat infections for all conditions except HIV and HSV-2.
Person-time was calculated as time from enrolment until first positive HIV test, last clinic attendance or end of study period. As in prior analyses with this cohort, we assumed that the effect of STI on HIV susceptibility would persist for 15 days after the infection was detected at a clinic visit [16] . We also estimated that HIV seroconversion would be detected 45 days after HIV acquisition, assuming that infection would occur, on average, at the midpoint between monthly visits. Thus, the total window of effect for any STI to influence HIV susceptibility was estimated to be 60 days (15 þ 45). That is, if a participant was diagnosed with an STI at visit Y, we assumed that the effect of the infection would last 60 days, so HIVacquired from the date of visit Yuntil Y þ 60 days was considered exposed to this STI.
We used Cox regression models to determine the hazard ratios (HRs) and 95% confidence intervals (95% CIs) for the effect of STIs on time to HIV seroconversion. First, we determined the incidence and correlates of HIV acquisition for the entire 20-year period. We conducted univariate analyses to determine whether individual risk factors were associated with HIV infection. Variables that were significantly associated with HIV in univariate analyses were included in the multivariate model. These included age, place of work, hormonal contraceptive use, number of sexual partners, unprotected intercourse, condom use in the past week and tobacco use. For each time period, the final Cox model included the confounding factors from the multivariate model for the entire 20-year period. We decided a priori to include all genital tract conditions in the final multivariate model. Population attributable risk percentage was calculated from the adjusted hazard ratio obtained from the final Cox models. The formula for PAR% ¼ pc (HR -1/ HR) Â 100%, where pc is the proportion of cases (at the visit level) that were exposed during the study. For each STI, we performed a linear test of trend to assess change in PAR% across time periods. Analyses were performed using IBM SPSS 19.0 (IBM, Kirkland, Washington, USA) and STATA 12 (StataCorp, College Station, Texas, USA).
Results
From 1993 to 2012, we enrolled 2301 HIV-seronegative women, of whom 1964 returned for at least one followup visit and were included in this analysis. Table 1 summarizes the baseline characteristics of these participants. Their median age was 28 years [interquartile range (IQR) [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Most (1310, 66%) reported working at a bar or restaurant. Alcohol use was common (1512, 77%). Except for bacterial vaginosis (N ¼ 642, 33%) and prevalent HSV-2 infection (N ¼ 1442, 73%), diagnosis of STIs and other genital tract conditions at baseline was less common. Figure 1 is a graphical presentation of the PAR% results.
This analysis excluded 437 women who did not return for follow-up after enrolment. Compared with the 1964 women included, those lost to follow-up were younger (median age 26 versus 28 years, P ¼ <0.001), more educated (9 versus 6% with 8-12 years of education, P ¼ 0.004), less likely to have ever been married (44 versus 52%, P ¼ 0.002), had fewer children (median 1 versus 2, P ¼ 0.03) and were less likely to use oral contraceptive pills (7 versus 12%, P ¼ 0.013). They were also less likely to report having more than one alcoholic drink per week (71 versus 77%, P ¼ 0.014) and less likely to have nonspecific cervicitis (5 versus 11%, P ¼ <0.001) or HSV-2 (15 versus 73%, P ¼ <0.001).
Apart from age and HSV-2, none of the other factors that differed between these two groups were significantly associated with HIV acquisition in this population.
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Discussion
In this 20-year prospective study of high-risk African women, HSV-2 and bacterial vaginosis consistently made the greatest contribution to their risk of HIV acquisition. The PAR% for these two conditions remained relatively high and stable over time, at around 50% for HSV-2, 15% for bacterial vaginosis and 7.5% for intermediate vaginal microbiota. The PAR% contributions for curable STIs were much lower because these conditions were present at far fewer visits. With the exception of candida, there were no significant temporal changes in PAR% across the four time periods for the other genital conditions. As such, our findings generally do not support our original hypothesis that the contribution of these STIs to HIV acquisition has changed over the 20 years observed in this cohort.
Our data suggest that chronic and recurrent genital conditions are larger drivers of transmission than incident STIs of shorter duration. Stated in terms of PAR%, prevalent or recurrent conditions contribute much more to PAR% than short duration incident infections. Of note, many HSV-2 seropositive patients have only asymptomatic shedding or clinically unrecognized genital ulcers [17] . Thus, the contribution of HSV-2 is crucial even when clinically apparent GUD is not identified.
Changes in STI prevalence and incidence, potentially related to control strategies such as condom use and syndromic management, could have influenced the PAR% contributed by some STIs. For example, syndromic STI management could have had a major impact on H. ducreyi. This organism is the cause of chancroid. This bacterial STI causes tender suppurative inguinal adenopathy and painful genital ulcers [18] , and may have played a substantial role in HIV transmission in Africa in the late 1980s and early 1990s [9] . In addition, HIV incidence in many countries began to decline well before antiretroviral therapy (ART) became available [19] , and strong STI programmes in the 1990s may have influenced these trends.
Prior trials of STI control to reduce HIV incidence targeted bacterial STIs. In our population of high-risk women, these STIs appear to be less important as drivers of transmission. Only one clinical trial of STI treatment for HIV-1 prevention demonstrated a statistically significant reduction in HIV incidence [20] . It has been suggested that the relative contribution of curable STIs to HIV acquisition may decline in the later stages of an HIV epidemic [5] . Other plausible explanations for the failure of most randomized controlled trial (RCT) interventions to reduce HIV incidence involve technical issues such as low incidence in some studies, greater than anticipated variability in community clusters, contamination between intervention and control communities, high attrition rates, declining rates of curable STIs, inappropriate site selection and weak/infrequent interventions [21, 22] . Two rigorously conducted trials targeted HSV-2 suppression, and these also failed to demonstrate an effect on HIV incidence [23, 24] . This effect has been attributed to the inability of acyclovir to suppress persistent immune activation triggered by HSV-2 infection that enhances HIVacquisition [25] . In addition, results from an in-vitro study demonstrated that CD4 þ and CD8 þ T cells persist at sites of HSV-2 reactivation [26] .
Given the finding that HSV-2 and bacterial vaginosis were the largest contributors to PAR% for HIV in women, it is interesting to note that there are important interactions between these two genital tract conditions. Women with bacterial vaginosis are more likely to acquire HSV-2 [27] . There is also evidence that prevalent and incident HSV-2 infection is associated with an increased prevalence of bacterial vaginosis [28, 29] . In general, HSV-2 and bacterial vaginosis appear to work together, with each driving the acquisition and/or transmission of the other. Devising innovative ways to mitigate the interactions between these conditions could help to reduce women's HIV risk.
Although most studies targeting genital tract infections as a strategy to reduce HIV incidence have not demonstrated efficacy, it remains plausible that prevention of herpes and bacterial vaginosis could reduce HIV incidence. Possible interventions for HSV-2 control include vaccination, preexposure prophylaxis to prevent HSV-2 acquisition and preventing bacterial vaginosis. Despite the disappointing results of the Herpevac trial, a herpes vaccine remains an important research priority [30] . The efficacy of prophylaxis, for example with valacyclovir, for HSV-2 negative individuals with an HSV-2 positive partner has not been tested. This approach to preexposure prophylaxis could be useful for reducing the risk of herpes, particularly in high-risk groups such as sex workers and young women in areas with a high incidence of both herpes and HIV.
1082 AIDS 2015, Vol 29 No 9 Table 4 . Prevalence (proportion of visits exposed) and contribution of genital tract conditions to HIV acquisition (PAR%) by time period.
Genital tract condition
Overall Although standard antibiotic regimens result in high cure rates for bacterial vaginosis, recurrences are common [31] . This study had several strengths. First, we utilized a large dataset that provided sufficient power to assess the associations between STIs and HIV. Second, monthly sampling to detect HIV and STIs, combined with rigorous measurement of potential confounding factors, provided a strong foundation for studying the associations between HIV and STIs. Finally, our 20-year analysis period for the Mombasa Cohort extended back to 1993. Although this may not align perfectly with the early-phase epidemic in Kenya, HIV incidence was still relatively high at that time (17 per 100 person-years during the earliest period of cohort follow-up) [35] . In addition, HIV incidence declined steadily over the two decades that the study was conducted. As a result, we were able to assess trends in the PAR% contributions of different STIs to HIV acquisition during an extended period that incorporated a wide range of HIV incidences.
Our study also had several limitations. First, STIs and HIV share a common mode of acquisition through contact with an infected partner. As such, our HR and PAR% estimates could be inflated due to confounding by sexual risk behaviour. We addressed potential confounding by adjusting for reported risk behaviours, including frequency of unprotected sex, number of sexual partners and number of sex episodes. Nonetheless, we recognize the potential for residual confounding. Second, the number of seroconverters decreased over time in the cohort. The modest number of events in the last 10 years limited the precision in our PAR% estimates for the last two time periods. This finding may reflect aggressive screening and treatment of STIs in the cohort and behaviour change counselling that the women receive once they have joined the cohort, or a general decrease in HIV incidence in the community, possibly as a result of the ART scale-up. Third, as with all observational studies, these results cannot definitively establish the presence causal associations between STIs and HIV acquisition. Fourth, differences in the sensitivity of laboratory methods for diagnosis of the different STIs may have contributed to the observed strength of the associations. However, the greatest difference in PAR% was likely contributed by the chronicity and frequent recurrence of HSV-2 and bacterial vaginosis, respectively. Fifth, we did not analyse the contribution of STIs such as syphilis and chancroid to HIV acquisition, because these data were not collected monthly. However, the overall prevalences of syphilis and chancroid in this cohort were low (2.4 and 0.03%, respectively), hence their contribution to HIVacquisition is likely to be minimal. Sixth, we did not evaluate the contribution of clearance of genital warts to HIV acquisition [36] , as this would have required a different approach to our analysis than for the other STIs for which PAR% was based on the presence rather than clearance. Finally, our study population was composed of high-risk women whose sexual risk behaviour is likely to be different from the general population, and this may limit generalizability. Changes in STI PAR% for HIV acquisition might also differ by geographic location, even for other populations of high-risk women. Despite these limitations, these results make a unique addition to the literature on STI and HIV interactions by directly evaluating trends in the contribution of different STIs to HIV acquisition over 2 decades of observation.
In summary, HSV-2 infection and bacterial vaginosis have remained the largest drivers of HIV acquisition in this cohort of high-risk women from 1993 through 2012. Although RCTs for prevention and treatment of genital tract infections have mostly failed to reduce HIV incidence, our study highlights the importance of HSV-2 and bacterial vaginosis as persistent drivers of HIV transmission. The findings suggest that strategic interventions that target STIs that are the main contributors to HIV risk could compliment other efficacious prevention approaches such as treatment as prevention [37] , preexposure prophylaxis [38] and male circumcision [39] . Novel approaches such as HSV-2 vaccination, preexposure prophylaxis to prevent HSV-2 acquisition and interventions that allow women to maintain healthy vaginal microbiota could provide useful strategies for improving women's health and potentially decreasing susceptibility to HIV. 
